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Renal artery stenosis is common especially in patients with
generalized atherosclerosis. It is frequently associated with
difficult-to-treat hypertension and with renal failure. There is
an ongoing debate about the appropriate screening and
treatment of atherosclerotic renal artery stenosis. Advances
in imaging and interventional devices offer new
opportunities, however, clinicians still have to decide
individually in every patient to treat or not to treat stenosis
with revascularization. This review evaluates the current
literature in order to help the physician to find the right
decision in this challenging clinical issue.
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Atherosclerosis is the main cause of renal artery stenosis. The
lesions mostly occur in ostial segments of the renal artery and
represent extension of adjacent aortic atherosclerotic plaque.1
Renovascular disease may induce renovascular hypertension
as well as ischemic nephropathy, an increasingly recognized
cause of end-stage renal failure in the US.2 This article will
focus on the management and treatment of patients with
atherosclerotic renal artery stenosis (ARAS) rather than on
patients with fibromuscular dysplasia, which was recently
reviewed in depth.3
Despite extensive research there is still a controversy
concerning the appropriate treatment of patients with ARAS.
Physicians have to balance for their patients the chances of
improvement regarding blood pressure and renal function
versus risks and costs of intervention. Efforts have focused
on finding reliable clinical parameters as well as improved
diagnostic techniques for predicting the outcome of ARAS,4–8
however, ideal solutions have not yet been found. It
is of note, that ARAS may occur alone (isolated anatomical
renal artery stenosis) or in association with hypertension,
renal insufficiency (ischemic nephropathy), or both.9
Hence screening tests for ARAS as well as interventional
procedures have to be discussed in the light of the
outcome of renovascular hypertension and ischemic nephro-
pathy.
Additionally it is worth taking in consideration the high
cardiovascular mortality of patients with ARAS and its
potential pathophysiological background. At present it is
uncertain, whether renovascular reconstruction can improve
the high mortality of these patients. Patients with ARAS are
mainly older than 60 years and frequently suffer from
widespread coexistent vascular disease. Five-year-survival has
been found to be as low as 45% in patients with bilateral
ARAS,10 decreasing to only 18% in those requiring dialysis
therapy.11
SCREENING FOR ARAS
In clinical practice it is essential to select patients with a high
likelihood of ARAS for the further screening. A clinical score,
developed by Krijnen et al.,4 may help in patient selection.
However, it is of note, that this score was evaluated in a pre-
selected population with a high probability of ARAS, because
only those patients with refractory hypertension or an incre-
ase of creatinine after therapy with angiotensin-converting
enzyme inhibitors were included into the study.4 This bias
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may have influenced the prevalence of ARAS, evaluated with
this score. Nevertheless, it seems useful to rely on several
clinical parameters, which increase the likelihood for patients
to have ARAS (Table 1). It is of note, that smoking as well as
a low body mass index less than 25 kg/m2 are predisposing
factors for ARAS.4
Meanwhile several non-invasive tests, such as captopril
test, color duplex sonography, captopril scintigraphy, com-
puted tomography angiography, and magnetic resonance
(MR) angiography are available, most with excellent
accuracy. Intra-arterial angiography including the measure-
ment of the pressure gradient is still the gold standard for the
diagnosis of ARAS, however, the diagnostic accuracy of even
this invasive procedure is also operator dependent.12,13
Usually renal arteriography is only indicated, if angioplasty
or stenting is intended.
Recently in a meta-analysis Vasbinder et al.6 compared
color duplex sonography with other non-invasive tests by
analyzing the area under the receiver operator curve
of these screening tests. They found computed tomography
angiography and MR angiography with higher diagnostic
accuracy than color duplex sonography for the diagnosis
of ARAS. Captopril scintigraphy and captopril test were
less accurate than color duplex sonography in this meta-
analysis.
However, diagnostic accuray may be only one of several
arguments, which lead the clinician to his favorite screening
method. Other criteria may be local availability of the test
and personal experience with it, as well as aspects of cost
benefit. There are some clear advantages for using color
duplex sonography as the first screening test of ARAS.
Sonography is an economic test, giving information about
the hemodynamic significance of stenosis and avoiding
nephrotoxic contrast media. In addition it is useful for the
follow-up after renal artery stenting.14,15 If direct visualiza-
tion of the renal arteries (Figure 1) is combined with
intrarenal scanning of the kidney, both accessible within
30 min of examination time, color duplex sonography has a
sensitivity and specificity of 90%, respectively, which is
appropiate for a single screening test for ARAS.16
Currently, it is at issue whether or not color duplex
sonography is useful to predict the outcome of revascular-
ization of ARAS.17,18 A single study showed a high predictive
value of resistive index, obtained in the segmental renal
arteries with color duplex sonography,8 however, subsequent
studies could not confirm these results.19–21
High operator dependency of color duplex sonography is
often felt to argue against this diagnostic tool in the screening
for ARAS. This argument, however, is referring to data of the
older literature, when high-end sonographic machines with
better penetration of the Doppler beam and faster hardware
were not available.22,23 Thus in recent years the success rate of
sonographic visualization of the renal arteries has improved
owing to further technical improvements as well as owing to
broader operator experience.
Additionally it is of note, that other renal imaging
techniques, such as computed tomography angiography,
and MR angiography, also show substantial operator
dependency including the gold standard, as mentioned
above.12,13 Recently Vasbinder et al.24 prospectively assessed
the diagnostic validity of computed tomography angiography
and MR angiography with two panels of three observers in
356 hypertensive patients who underwent digital subtraction
angiography for detection of renal artery stenosis. Moderate
interobserver agreement was found, with K values ranging
from 0.59 to 0.64 for computed tomography angiography
and 0.40 to 0.51 for MR angiography.
Owing to the lack of clear evidence in the literature for
diagnostic superiority of one technique, the physician, who
has to screen patients for ARAS, will choose this technique,
he is either performing himself (e.g., color duplex sono-
Table 1 | Clinical findings compatible with atherosclerotic
renal artery stenosis
Hypertension
Abrupt onset of hypertension at or after the age of 50 years
Accelerated or malignant hypertension
Refractory hypertension (not responsive to therapy with X3 drugs)
Renal abnormalities
Unexplained azotemia
Azotemia induced by treatment with an ACE inhibitor
Sonographic length of the kidney o8 cm
Other findings
Unexplained congestive heart failure or acute pulmonary edema
Abdominal bruit, flank bruit, or both
Systemic atherosclerotic vascular disease
Severe retinopathy
Current or former smoker
Low body mass index (o25 kg/m2)
ACE, angiotensin-converting enzyme.
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Figure 1 | Color duplex sonography of right-sided ostial renal
artery stenosis. High peak systolic velocity of 3.36 m/s is obtained
within in the stenosis. The green color indicates high blood flow
velocity with turbulences near the stenosis. Low mean resistive index
(RI¼ 47) of the right kidney is an indirect sign of significant
stenosis.
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graphy) or that is easily available, reliable, and valid in his
personal experience.
TREATMENT OF ARAS
Potential consequences of conservative management
Many nephrologists tend to be conservative towards
reconstruction of ARAS as some disappointing results were
published in three randomized prospective studies, which
compared medical treatment with angioplasty in patients
with ARAS.25–27 In all three studies there is no evidence that
angioplasty improves the outcome of blood pressure in
comparison to medical treatment.
However, if the clinician prefers medical treatment, the
natural history of ARAS has to be considered. It is of note
that the progression of ARAS depends on the grading of
stenosis at the time of the initial diagnosis. Caps et al.28
monitored patients with ARAS by color duplex sonography
during a 3-year follow-up. Progressive narrowing was
reported in 18, 28, and 49% for renal arteries that initially
were classified as normal, o60% stenosis, and X60%
stenosis, respectively. However, approximately half of the
patients do not show disease progression. Therefore the
initial screening test should enable the clinician to perform a
reliable grading of the stenotic lesion. If the renal artery is
narrowed by 70–80%, a 40% decline in renal perfusion
pressure occurs, termed ‘critical stenosis’.22 It is of note, that
several studies dealing with the treatment of ARAS, included
patients with the lower limit of X50% stenosis.8,25,27
Therefore some negative results should be cautiously
interpreted. If the clinician favors conservative treatment,
regular monitoring (e.g., every 6 months) is recommended to
detect those patients with progression of ARAS. Currently
color duplex sonography seems to be the ideal tool for this
monitoring.16 In the Dutch Renal Artery Stenosis Interven-
tion Cooperative (DRASTIC) study, the largest of the three
randomized studies, eight occlusions of renal arteries
occurred in the group of patients with medical treatment
in contrast to no occlusion in the group of patients with
interventional treatment.25
Medical treatment of patients with ARAS should also
include statins as well as low doses of acetyl-salicyl acid in
addition to the cessation of smoking, although any evidence
from prospective studies showing significant benefit for these
patients is missing. It is clinical common sense that aggressive
lipid lowering may have the same effect of atherosclerotic
regression in the renal arteries as it has been shown for
coronary arteries.29 Antihypertensive treatment may also
include angiotensin-converting enzyme inhibitors in patients
suspected for ARAS, if renal function, for example, serum
creatinine, is controlled in a close period of time. Van de Ven
et al.30 investigated the effects on renal function in 108
patients at risk for severe bilateral atherosclerotic reno-
vascular disease. In 62 of the 108 patients serum creatinine
increased within 4 days or 2 weeks, respectively, however, no
case of acute renal failure was encountered, because
medication was stopped in time.30
Regarding patient survival Conlon et al.31 have shown in
3987 patients, who underwent abdominal aortography
immediately following coronary angiography, that 4-year-
adjusted survival of patients with 50, 75, and X95% ARAS
was 70, 68, and 48%, respectively. Some recent data from the
literature may help to understand this obvious relationship
between stenotic grading and patient survival.
Higashi et al.32 have shown that excessive oxidative stress
is involved, at least in part, in impaired endothelium-
dependent vasodilatation in patients with renovascular
hypertension. Recently Wright et al.33 found significantly
more cardiovascular comorbidity in 79 patients with ARAS
than in 50 control patients (78.5 versus 46%). Patients with
ARAS had greater prevalence of left ventricular hypertrophy
and left ventricular diastolic dysfunction, greater left
ventricular mass index, and left ventricular end-diastolic
volume index than control subjects. The higher levels of
angiotensin II in patients with ARAS may explain several
morphological and functional abnormalities in these pa-
tients. Further studies should reveal, whether renal artery
reconstruction improves patient survival, which has not yet
been clearly shown. A meta-analysis of the three randomized
trials comparing medical treatment with balloon angioplasty
in a total of 210 patients may give a hint in this direction.34
The authors reported 10 major cardiovascular or reno-
vascular complications in the balloon angioplasty group,
compared with 26 in the medical therapy group, which might
have been significantly different, if a larger group of patients
would have been studied.34
In summary of the current data it can be concluded that
medical treatment of ARAS is not without risk for the
patients.
The choice of treatment
In 1993 a randomized study compared the outcome of
angioplasty with that of surgical reconstruction of ARAS in
58 patients less than 70 years. The primary and secondary
patency rates of surgery were significantly higher than those
of angioplasty, for example, 96 and 97% versus 75 and 90%,
respectively.35 However, renal artery stent placement was not
routinely available at that time. ARAS typically occurs in
elder patients (470 years) with an increased risk of
cardiovascular and cholesterol-embolic complications during
surgical repair of the renal artery. Nevertheless even younger
patients with complex renovascular diseases, for example,
renal artery aneurysm or failed endovascular procedures, still
have a benefit from renal artery surgery.
As the introduction of stents patients with ostial ARAS,
frequently showing the problem of elastic recoil after
angioplasty, should be treated by primary stent placement.15
However, it is of note that a prospective randomized study
comparing renal artery stenting with angioplasty alone at 6
months follow-up did not show any difference of blood
pressure outcome between both groups, although the
primary patency rate was significantly improved in the
patients with stents (75 versus 29%, respectively).36
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Renovascular hypertension
Three single randomized trials did not find any beneficial
effect of angioplasty concerning the outcome of blood
pressure in comparison to medical treatment.25–27 However,
two meta-analyses of these studies, each involving a total of
210 patients, both found a significantly better reduction of
blood pressure with angioplasty, rather than with medical
treatment.34,37 It can be hypothesized that the number
of patients in each randomized trial was to low to show
any difference of both treatments. For the daily practice,
perhaps, we can learn something from important details of
the DRASTIC study. From 50 patients originally assigned
for drug therapy 22 patients underwent angioplasty
after 3 months, because diastolic blood pressure was 95 mm
Hg or higher despite treatment with three or more
antihypertensive drugs.25 At this time, before angioplasty
was performed in the 22 patients, systolic and diastolic
blood pressure as well as the number of antihypertensives
were statistically different from those of the 28 patients,
who exclusively received medical treatment. After 12 months
the final intention-to-treat-analysis of the entire group
of 50 patients showed no difference of blood pressure,
which may have been influenced by the changes of
treatment.
These data clearly demonstrate that even those patients
with intractable hypertension may have a high likelihood of
benefit from reconstruction of the renal artery.
Ischemic nephropathy
Significant ARAS potentially increases the risk of renal
atrophy as well as progressive loss of renal function. In none
of the three prospective randomized studies there was any
consistent change in renal function between the angioplasty
and medical-therapy groups.25–27 However, evaluation of
renal function was not the primary end point and probably
the follow-up of the mentioned studies (6–12 months) was
too short to detect any difference. Additionally it is
noteworthy that patients with severe renal dysfunction were
excluded in all three studies.
The slope of decline of the glomerular filtration rate in the
recent history of patients with ARAS seems to be more
important rather than the level of renal function at the time
of admission. Beutler et al.38 prospectively studied the long-
term effects of stenting on kidney function in patients with
renal insufficiency and ostial ARAS. During a 1-year follow-
up in 26 of 56 patients with previous stable renal dysfunction
renal artery stenting did not improve serum creatinine levels.
However, in the remaining 30 patients with previously
deteriorating renal function serum creatinine significantly
improved after stenting und remained stable during follow-
up monitoring. In another group of patients with global
renovascular obstruction (bilateral stenosis or ARAS in the
presence of a solitary or single functioning kidney) the
previously negative slope of reciprocal serum creatinine
became positive in 18 of 33 patients and less negative in
additional seven patients.39
In conclusion the change of serum creatinine, especially in
the recent patient’s history, is rather more important for the
physician than the absolute level of kidney function.
CONCLUSION
Atherosclerotic renovascular disease, commonly seen in
clinical practice, is in part a progressive disorder associated
with increased cardiovascular morbidity and mortality.
Physicians have to distinguish patients with a high likelihood
of treatment benefit from those with incidental ARAS.
Answers on the following issues may help the clinician to find
the right decision for his individual patient with ARAS: Is
there any hypertension that is in fact refractory to
antihypertensive treatment? What is the slope of renal
function in the recent patient’s history? Does the regular
non-invasive monitoring show progression of renal artery
disease? Further prospective randomized studies, such as the
recently started ‘cardiovascular outcomes with renal athero-
sclerotic lesions (CORAL) study’ with expected completion
in the year 2010,40 have to show, whether revascularization of
the renal artery may improve the high cardiovascular
mortality of patients with ARAS.
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